(S)-2-amino-3-(1H-imidazol-4-yl)-N-(2-(naphthalen-2-yl)ethyl)propanamide

ID: ALA5094081

PubChem CID: 141882868

Max Phase: Preclinical

Molecular Formula: C18H20N4O

Molecular Weight: 308.38

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  N[C@@H](Cc1c[nH]cn1)C(=O)NCCc1ccc2ccccc2c1

Standard InChI:  InChI=1S/C18H20N4O/c19-17(10-16-11-20-12-22-16)18(23)21-8-7-13-5-6-14-3-1-2-4-15(14)9-13/h1-6,9,11-12,17H,7-8,10,19H2,(H,20,22)(H,21,23)/t17-/m0/s1

Standard InChI Key:  YHEJFEJJFPIYNO-KRWDZBQOSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
    2.4363   -0.3283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7218    0.0840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7218    0.9056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4317    1.3144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1448    0.9036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1448    0.0861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8567   -0.3226    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5608    0.0914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5608    0.9047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8485    1.3119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0104   -0.3266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2990    0.0840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4124   -0.3266    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1247    0.0845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1247    0.9071    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8367   -0.3265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5486    0.0844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2605   -0.3265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0110    0.0076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5608   -0.6029    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1500   -1.3144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3463   -1.1436    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8367   -1.1484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  2  0
  4  3  1  0
  5  4  2  0
  6  5  1  0
  1  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  5 10  1  0
 11  2  1  0
 12 11  1  0
 13 12  1  0
 14 13  1  0
 14 15  2  0
 16 14  1  0
 16 17  1  0
 17 18  1  0
 19 18  2  0
 20 19  1  0
 21 20  1  0
 22 21  2  0
 22 18  1  0
 16 23  1  1
M  END

Alternative Forms

1. Parent:

   

   ALA5094081

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 308.38

Molecular Weight (Monoisotopic): 308.1637

AlogP: 1.79

#Rotatable Bonds: 6

Polar Surface Area: 83.80

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.09

CX Basic pKa: 7.84

CX LogP: 1.41

CX LogD: 0.83

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.65

Np Likeness Score: -0.27

References

1.  (2020)  Enhancers of neurolysin activity, 

2. Rahman MS, Kumari S, Esfahani SH, Nozohouri S, Jayaraman S, Kinarivala N, Kocot J, Baez A, Farris D, Abbruscato TJ, Karamyan VT, Trippier PC..  (2021)  Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.,  64  (17.0): [PMID:34436882] [10.1021/acs.jmedchem.1c00759]

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data